These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 32164491)

  • 1. Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction.
    Hartmann A; Paparoupa M; Volkmer BG; Rompel R; Wittig A; Schuppert F
    J Oncol Pharm Pract; 2020 Oct; 26(7):1774-1779. PubMed ID: 32164491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
    Nada A; Bhat R; Cousins J
    Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy-induced autoimmune hypophysitis.
    Valecha G; Pant M; Ibrahim U; Atallah JP
    J Oncol Pharm Pract; 2019 Jan; 25(1):217-220. PubMed ID: 28825378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An autopsy case study of lymphocytic hypophysitis induced by nivolumab treatment for esophageal malignant melanoma.
    Okabe N; Kobayashi T; Furuse J; Fujiwara M; Kamma H
    Pathol Int; 2021 Dec; 71(12):831-836. PubMed ID: 34506687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab induced hypophysitis in an advanced RCC patient.
    Korkmaz Yilmaz M; Gulturk I; Tacar SY; Yilmaz M
    J Oncol Pharm Pract; 2022 Apr; 28(3):759-762. PubMed ID: 35006033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
    Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors.
    Azari AE; Stratton R; Singh A
    Rheumatology (Oxford); 2021 May; 60(5):e167-e168. PubMed ID: 33280022
    [No Abstract]   [Full Text] [Related]  

  • 9. [A Case of Metachronous Occurrence of Interstitial Pneumonitis and Hypophysitis Following Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma].
    Hayase T; Washino S; Mayumi S; Yazaki K; Nakamura Y; Oshima M; Konishi T; Saito K; Miyagawa T
    Hinyokika Kiyo; 2021 Jun; 67(6):239-243. PubMed ID: 34265899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint Inhibitor Induced Acute Liver Failure.
    Ezeani C; Ugochukwu O; Johnson A; Lavie D; Chauvin R
    J Investig Med High Impact Case Rep; 2024; 12():23247096241261505. PubMed ID: 38895944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endocrine side effects of checkpoint inhibitors].
    Chen WJY; Krul-Poel YHM; Roth C; Labots M; van den Eertwegh AJM; Dreijerink KMA
    Ned Tijdschr Geneeskd; 2019 Oct; 163():. PubMed ID: 31714042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database.
    Tang Q; Han Y; Song M; Peng J; Zhang M; Ren X; Sun H
    Medicine (Baltimore); 2024 Mar; 103(13):e37587. PubMed ID: 38552079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances.
    Malikova H; Holesta M; Fialova A; Arenbergerova M; Weichet J
    Neuro Endocrinol Lett; 2018 Sep; 39(3):196-204. PubMed ID: 30431741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
    Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
    Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint Inhibitor-Associated Hypophysitis.
    Chang LS; Yialamas MA
    J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
    [No Abstract]   [Full Text] [Related]  

  • 17. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort.
    Kotwal A; Rouleau SG; Dasari S; Kottschade L; Ryder M; Kudva YC; Markovic S; Erickson D
    J Investig Med; 2022 Apr; 70(4):939-946. PubMed ID: 34969937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
    Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
    J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management.
    Tiu C; Pezaro C; Davis ID; Grossmann M; Parente P
    Asia Pac J Clin Oncol; 2015 Jun; 11(2):190-4. PubMed ID: 25855890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.